Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...

Doctors have said access to the drug is a "postcode lottery" as Sky News analysis reveals just 800 people have been ...

There is no perfect definition of healthy or unhealthy food. There is no perfect system of regulation. But I believe that ...

The former immigration minister, who lost four stone in 12 months, said the drug had aided him at the start of his bid to ...

Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

More than 15,000 dangerously overweight Scots were sent to specialist clinics last year amid a rising obesity epidemic.

Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...